VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.58 Million in Insulet Corporation $PODD

Key Points

• Virginia Retirement Systems acquired 10,360 shares of Insulet, valued at approximately $1.58 million, during the second quarter. Several other institutional investors also initiated or increased positions in the company.
• Insulet reported quarterly earnings of $1.66 per share, exceeding estimates of $1.47, while revenue rose 23.5% year over year to $801.7 million.
• Analyst sentiment is mixed: 14 analysts rate the stock a Buy, 11 rate it Hold and two rate it Sell, producing a consensus Hold rating and an average price target of $195.40.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 10,360 shares of the medical instruments supplier's stock, valued at approximately $1,577,000.

Other large investors have also bought and sold shares of the company. OP Asset Management Ltd bought a new stake in Insulet during the 1st quarter worth about $1,513,000. OneDigital Investment Advisors LLC bought a new position in shares of Insulet in the 2nd quarter valued at about $6,741,000. SEB Asset Management AB bought a new position in shares of Insulet in the 1st quarter valued at about $24,700,000. DNB Asset Management AS increased its position in shares of Insulet by 21.1% in the fourth quarter. DNB Asset Management AS now owns 58,161 shares of the medical instruments supplier's stock valued at $16,532,000 after acquiring an additional 10,148 shares during the last quarter. Finally, Jupiter Asset Management Ltd. acquired a new stake in shares of Insulet in the fourth quarter valued at about $66,644,000.

Insulet Stock Performance

Shares of PODD stock opened at $131.96 on Friday. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.06 and a beta of 1.08. The company has a 50-day simple moving average of $152.36 and a 200 day simple moving average of $173.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period last year, the business posted $1.17 earnings per share. The business's revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PODD shares. Raymond James Financial reiterated an "outperform" rating and set a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, June 24th. Robert W. Baird set a $175.00 price target on shares of Insulet in a research report on Thursday, August 6th. The Goldman Sachs Group reiterated a "buy" rating and issued a $205.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Finally, Oppenheimer downgraded shares of Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.